Overview

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Status:
RECRUITING
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose
Phase:
PHASE1
Details
Lead Sponsor:
Atea Pharmaceuticals, Inc.
Treatments:
AT-511